‘Right-Sizing’ Surveillance Intervals for CRC: Considerations for Now and the Future

The 2020 guidelines for surveillance colonoscopy have steered clinicians toward more appropriate surveillance ...

AUGUST 25, 2025

Inflammatory Diet Associated With Worse Survival in Patients With Stage III Colon Cancer

Results from a large prospective cohort study reveal that eating a less inflammatory diet may improve survival for ...

AUGUST 20, 2025

Circulating Tumor DNA Blood Test Shows Promise for Colorectal Cancer Screening

A circulating tumor DNA–based blood test demonstrated its ability to accurately detect colorectal cancer ...

AUGUST 6, 2025

Mixed Results Seen for PREEMPT CRC Screening Test

The PREEMPT CRC study met its primary end points but with a lower magnitude of benefit than investigators had ...

JULY 16, 2025

Structured Exercise Improves Survival in Stage II/III Colon Cancer

A structured exercise program after adjuvant chemotherapy in patients with high-risk stage II or III colon cancer ...

JUNE 2, 2025

Simple Patient Outreach Led to 50% Drop in CRC Mortality Rates

Offering flexible options for CRC screening doubled screening rates, cut cancer incidence by a third, halved ...

MAY 14, 2025

FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...

APRIL 9, 2025

Novel Stool-Based CRC Screening Test Yields Impressive Early Results

A stool-based test that combines biomarkers of CRC using an AI–driven algorithm showed high sensitivity for ...

FEBRUARY 17, 2025

FDA Approves Lumakras With Vectibix for KRAS G12C–Mutated Colorectal Cancer

The FDA has approved sotorasib (Lumakras, Amgen) with panitumumab (Vectibix, Amgen) for adult patients with KRAS ...

JANUARY 21, 2025

FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...

DECEMBER 30, 2024

FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer

The FDA granted accelerated approval to encorafenib (Braftovi, Array BioPharma, a subsidiary of Pfizer) with ...

DECEMBER 23, 2024

Large Analysis Finds No Need for 5-FU Bolus in Some GI Cancer Regimens

Omitting a bolus of 5-FU as part of a FOLFOX, FOLFIRI or FOLFIRINOX regimen in patients with metastatic ...

DECEMBER 6, 2024